THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMATHE COLLABORATION LEVERAGES EVOTEC’S DATA-DRIVEN EVOIR&D PLATFORM FOR INTEGRATED DISCOVERY AND DEVELOPMENT OF FIRST-IN-CLASS THERAPIES AND ALMIRALL’S EXPERTISE IN MEDICAL DERMATOLOGY
HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / Might 19, 2022 / Evotec SE (Frankfurt Inventory Alternate:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a worldwide biopharmaceutical firm centered on pores and skin well being, introduced at present a multi-target alliance in Medical Dermatology. The businesses purpose to find and develop novel therapeutics for extreme pores and skin illnesses, together with immune-mediated inflammatory situations resembling atopic dermatitis and non-melanoma pores and skin most cancers resembling basal cell carcinoma.
Sponsored content material:
The alliance will leverage Evotec’s absolutely built-in multimodality platform and mix it with Almirall’s main experience in Medical Dermatology. Each companions will contribute drug targets within the analysis course of. Leveraging the Firm’s end-to-end built-in, AI/ML-driven EVOiR&D platform, Evotec shall be answerable for drug discovery and pre-clinical growth. Almirall will lead the scientific growth and advertising.
Below the settlement, Evotec receives an undisclosed upfront fee, analysis funds, in addition to success-based milestones of doubtless as much as € 230 m per programme and royalties on web gross sales within the excessive single-digit proportion vary.
Dr Werner Lanthaler, Chief Govt Officer of Evotec, commented: “We’re very completely happy to enter this collaboration with Almirall, one of many leaders within the subject of Medical Dermatology. The collaboration has the potential to ship superior first-in-class therapeutic choices for a lot of sufferers affected by extreme pores and skin illnesses resembling atopic dermatitis or basal cell carcinoma. We’re wanting ahead to leveraging the complementary experience of Evotec and Almirall in an effort to develop promising new drug candidates.”
Dr Karl Ziegelbauer, Chief Scientific Officer of Almirall, said: “We’re very excited in regards to the strategic alliance with Evotec and consider that combining Almirall’s expertise and know-how in Medical Dermatology with Evotec’s built-in drug discovery and preclinical growth small molecule platform will allow us to ship novel options for sufferers affected by auto-immune pores and skin illnesses or frequent types of pores and skin most cancers.”
Sponsored content material: OurLifeStore.com is a veteran owned e-commerce with over 40k objects at nice costs & all the time free delivery
Almirall is a worldwide biopharmaceutical firm centered on pores and skin well being. We collaborate with scientists and healthcare professionals to deal with affected person’s wants via science to enhance their lives. Our Noble Function is on the core of our work: “Rework the sufferers’ world by serving to them understand their hopes and goals for a wholesome life”. We spend money on differentiated and ground-breaking medical dermatology merchandise to carry our modern options to sufferers in want.
The corporate, based in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Inventory Alternate and is a member of the IBEX35 (ticker: ALM). All through its 79-year historical past, Almirall has retained a robust give attention to the wants of sufferers. Presently, Almirall has a direct presence in 21 international locations and strategic agreements in over 70, with about 1,800 workers. Whole revenues in 2021 have been 836.5 million euros. For extra data, please go to almirall.com.
Media contact Almirall:
Cellphone: (+34) 600 430 581
Investor Relations contact:
Pablo Divasson del Fraile
Cellphone: (+34) 93 291 3087
Company Communications contact:
Cellphone: (+34) 671 580 438
ABOUT EVOTEC SE
Evotec is a life science firm with a singular enterprise mannequin that delivers on its mission to find and develop extremely efficient therapeutics and make them obtainable to the sufferers. The Firm’s multimodality platform includes a singular mixture of modern applied sciences, knowledge and science for the invention, growth, and manufacturing of first-in-class and best-in-class pharmaceutical merchandise. Evotec leverages this “Information-driven R&D Autobahn to Cures” for proprietary tasks and inside a community of companions together with all High 20 Pharma and over 800 biotechnology firms, tutorial establishments, in addition to different healthcare stakeholders. Evotec has strategic actions in a broad vary of at present underserved therapeutic areas, together with e.g. neurology, oncology, in addition to metabolic and infectious illnesses. Inside these areas of experience, Evotec goals to create the world-leading co-owned pipeline for modern therapeutics and has to-date established a portfolio of greater than 200 proprietary and co-owned R&D tasks from early discovery to scientific growth. Evotec operates globally with greater than 4,200 extremely certified folks. The Firm’s 15 websites supply extremely synergistic applied sciences and companies and function as complementary clusters of excellence. For added data please go to www.evotec.com and observe us on Twitter @Evotec and LinkedIn.
This announcement comprises forward-looking statements regarding future occasions, together with the proposed providing and itemizing of Evotec’s securities. Phrases resembling “anticipate,” “consider,” “might,” “estimate,” “count on,” “intend,” “might,” “may,” “plan,” “potential,” “ought to,” “goal,” “would” and variations of such phrases and related expressions are supposed to determine forward-looking statements. Such statements embody feedback relating to Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D bills. These forward-looking statements are primarily based on the knowledge obtainable to, and the expectations and assumptions deemed cheap by Evotec on the time these statements have been made. No assurance will be provided that such expectations will show to have been appropriate. These statements contain identified and unknown dangers and are primarily based upon quite a lot of assumptions and estimates, that are inherently topic to vital uncertainties and contingencies, lots of that are past the management of Evotec. Evotec expressly disclaims any obligations or endeavor to launch publicly any updates or revisions to any forward-looking statements contained herein to mirror any change in Evotec’s expectations with respect thereto or any change in occasions, situations or circumstances on which any assertion is predicated.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of World Company Communications & Advertising and marketing, Cellphone: +49.(0)40.56081-255, [email protected]
IR Contact Evotec SE:
Volker Braun, SVP Head of World Investor Relations & ESG, Cellphone: +49.(0)40.56081-775, [email protected]
SOURCE: Evotec AG
View supply model on accesswire.com: